Skip to content

Enforcement Highlights

  • About Us
  • Contact
  • Cookie Policy
Enforcement
Highlights

Covering SEC, CFTC, FINRA, PCAOB, States, Exchanges, & FCA Enforcement Activities

SEC Continues to Prioritize COVID Fraud Cases

On September 25, 2020, the SEC filed a civil injunctive action against a microcap company, Arrayit Corp., and its President and Chief Science Officer for falsely stating in March-April 2020 that Arrayit had developed a COVID-19 blood test when it had not yet purchased materials to make a test. The SEC further alleged that the test had been submitted for emergency approval, and falsely boasted to investors that there was a high demand for the test.

As we previously discussed, over the past several months the SEC has been using trading suspensions to prevent fraud and investor harm related to the COVID-19 pandemic. The SEC has pressed forward with cases charging securities fraud for COVID-19-related misrepresentations. On May 14, the SEC charged Applied BioSciences Corp. with securities fraud based on the company’s public statements with regard to offering products to combat COVID-19. The SEC had previously suspended trading of Applied BioSciences Corp.’s stock. Similarly, Praxsyn Corporation, whose stock the SEC had also halted trading of, was charged with fraud for falsely stating the company’s ability to secure large quantities of masks used to protect against COVID-19.

Because SEC trading suspensions are typically followed by investigations, and eventually by lawsuits, we can expect to see more litigation by the Division as the year progresses. Thus far, the agency appears to be focusing on microcap fraud rather than on more sophisticated COVID-related disclosure issues associated with listed public companies. These actions are part of the SEC’s larger Coronavirus (COVID-19) Response across its various divisions.

Subscribe and Receive Alerts to New Articles

SUBSCRIBE
October 7, 2020
Written by: Michael MacPhail
Category: Public Companies, Accounting, and Auditing

Post navigation

Previous Previous post: SEC Enforcement’s First Public Company Cases Resulting from its EPS Initiative
Next Next post: SEC Settles Enforcement Action against Private Equity Firm for Beneficial Ownership Reporting Violations

Subscribe to Email Alerts

Categories

  • Compliance and Supervision
  • Futures and Derivatives
  • Hedge Funds and Private Equity
  • Insider and Manipulative Trading
  • Investment Advisers and Broker Dealers
  • Municipal Bond Offerings
  • Public Companies, Accounting, and Auditing

©2023 Faegre Drinker Biddle & Reath LLP. All Rights Reserved. Lawyer Advertising.

  • About Us
  • Contact
  • Cookie Policy
We use cookies to improve your experience with our website. By browsing our site, you are agreeing to the use of cookies. For more information about how we use cookies, please review our privacy policy and cookie policy. OK
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT